Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06930625 · ClinicalTrials.gov registry record · Phase 3

A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs

A Phase 3 study of Acromegaly, sponsored by Debiopharm International.

Recruiting
Registry status
Phase 3
Development phase
119
Enrollment target
20
Study locations

NCT06930625 is a Phase 3 study of Acromegaly that is actively recruiting participants, run by Debiopharm International. The registered enrollment target is 119 participants, above the 92-participant average among 13 other Acromegaly trials with a reported enrollment target (29% higher). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06930625, a Phase 3 study of Acromegaly, is actively recruiting participants, sponsored by Debiopharm International.

RECRUITING
Registry status
Phase 3
Development phase
119 participants
Enrollment target
20
Study locations

Study Summary

The primary purpose of this study is to assess the effect of Debio 4126 in the maintenance of the levels of insulin-like growth factor 1 (IGF-1) ≤1x upper limit of normal (ULN) in the double-blind period (Period 1) in comparison to placebo at week 36.

Conditions Studied

Acromegaly

Interventions

  • DRUG Placebo
  • DRUG Debio 4126

Study Locations (20)

Other

  • Medical University Graz - Graz
  • Medizinische Universitaet Wien - Division of Endocrinology and Metabolism - Vienna
  • UZ Gent - Ghent
  • CETI - Centro de Estudos em Terapias Inovadoras - Curitiba
  • Nucleo de Pesquisa e Desenvolvimento de Medicamentos (NPDM) - Fortaleza
  • Instituto Estadual do Cérebro Paulo Niemeyer (IECPN) - Rio de Janeiro
  • Hospital das Clinicas - University of Sao Paulo Medical School - São Paulo
  • University Specialized Hospital for Active Treatment of Endocrinology Akad. lv Penchev EAD - Sofia
  • Rigshospitalet, Blegdamsvej 9 - Copenhagen
  • Zealand University Hospital - Køge
  • East Tallinn Central Hospital - Tallinn

Ohio

  • The Cleveland Clinic - Cleveland
  • The Ohio State University - Columbus

California

  • Cedars Sinai Medical Center - Los Angeles

Illinois

  • Northwestern University - Chicago

Massachusetts

  • Harvard Medical School - Boston

Missouri

  • Washington University-School of Medicine - St Louis

Nevada

  • Palm Research Center Inc - Las Vegas

Oregon

  • Oregon Health & Science University - Portland

Trial Details

FieldValue
Enrollment Target 119 participants
Start Date 2025-11-26
Est. Completion 2029-03
Phase Phase 3

Sponsor

Debiopharm International

30 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06930625

The ClinicalTrials.gov registry entry for NCT06930625 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 92-participant average among 13 other Acromegaly trials with a reported enrollment target (29% higher). The listed sponsor is Debiopharm International, which has 30 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acromegaly appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06930625 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, Ohio, California.

Frequently Asked Questions

What is clinical trial NCT06930625 about?

NCT06930625 is a clinical study titled "A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs". The primary purpose of this study is to assess the effect of Debio 4126 in the maintenance of the levels of insulin-like growth factor 1 (IGF-1) ≤1x upper limit of normal (ULN) in the double-blind period (Period 1) in comparison to placebo at week 36.

What is the current status of trial NCT06930625?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 119 participants. The study started on 2025-11-26. Estimated completion is 2029-03.

What conditions does trial NCT06930625 study?

This clinical trial studies the following conditions: Acromegaly.

What interventions are being tested in trial NCT06930625?

The interventions under investigation include: Placebo (DRUG), Debio 4126 (DRUG).

Who is sponsoring clinical trial NCT06930625?

This trial is sponsored by Debiopharm International, which has 30 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06930625 being conducted?

This trial has 20 study locations across California, Illinois, Massachusetts, Missouri, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acromegaly

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acromegaly

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.